Skip to Main Content
An official website of the United States government
Epidemiology and Genomics Research Program

Cancer Treatment-Related Cardiotoxicity

Need Help?

Have questions about this topic or need additional assistance?

Contact Us

Nonniekaye F. Shelburne, CRNP, MS, AOCN
Program Director, Clinical and Translational Epidemiology Branch
nshelburne@mail.nih.gov

Overview

Cancer treatment today employs a combination of chemotherapy, radiotherapy, and surgery to prevent recurrence, prolong life and provide cure. However, many of these treatments can cause devastating cardiovascular complications for the patient such as heart failure, myocardial ischemia/infarction, hypertension, thromboembolism, and arrhythmias. Developing and understanding optimal prevention, early detection and treatment strategies for cardiotoxicity related to anticancer treatment is a critical aspect of cancer patient care, and may have a significant impact on the overall prognosis and survival of cancer patients. These important clinical events are a significant challenge for both cardiologists and oncologists and will continue to be in the future, particularly due to an increasing aging population of patients with cancer and the introduction of many new targeted cancer therapies.

Efforts to identify individual toxicity risks and prevention strategies support the National Cancer Institute's (NCI) goal of reducing the burden of cancer diagnoses and treatment outcomes. NCI's vision for the future includes precision medicine that not only provides effective therapy for eradicating disease, but also maintains the function of normal tissues, thus decreasing the burden of cancer throughout the survivorship spectrum.

Funding Opportunities

NCI-sponsored notices of funding opportunities related to cancer treatment-related cardiotoxicity research include:

  • Notice of Special Interest: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity - expires November 6, 2024

EGRP joins with other NCI Divisions, Offices, and Centers and other Institutes and Centers at the National Institutes of Health (NIH) to fund grant applications submitted in response to funding opportunities. View the full list of EGRP funding opportunities.

Workshops, Conferences, and Webinars

The Epidemiology and Genomics Research Program is dedicated to full accessibility and the inclusion of individuals with disabilities. We continuously strive to improve our recorded webinars' accessibility, recognizing that some may be more accessible than others. If you encounter any recorded webinar that does not meet your accessibility needs, please feel free to reach out to NCIDCCPSEGRPComms@mail.nih.gov.